# US 7,745,156 B2 · Methods for diagnosis and treatment of epithelial-derived cancers > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,745,156 B2 - Document ID: US7745156B2 - Status: Granted - Kind: B2 - Application number: 11/880,650 - Filed: 2007-07-23 - Published: 2009-06-11 - Granted: 2010-06-29 - Earliest claimed: 2001-11-27 - Assignees: UCB Pharma S.A. - Inventors: Jonathan Alexander Terrett - Web page: https://patentgrep.com/patent/US7745156B2 ## CPC - G01N 33/57535: of the large intestine, e.g. colon, rectum or anus - A61P 35/00: Antineoplastic agents - C07H 21/04: with deoxyribosyl as saccharide radical - G01N 33/57525: of the liver or pancreas - G01N 2333/70575: NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154 - G01N 2333/70578: NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95 - G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor) - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13) ## Abstract The present invention relates to the use of a polypeptide (CD27L) for diagnosis of epithelial-related cancers, in particular kidney cancer e.g. renal cell cancer and colorectal cancer, e.g. colon cancers, as well as in methods of treatment of such cancers. ## Claims ### Claim 1 A method of screening for and/or diagnosis of epithelial-derived cancer in a subject, and/or monitoring the effectiveness of epithelial-derived cancer therapy, which comprises the step of detecting and/or quantifying in a biological sample obtained from said subject, a CD27L polypeptide which comprises or consists of the amino acid sequence of SEQ ID NO: 2. ### Claim 2 (depends on 1) The method of claim 1, wherein the level of said polypeptide is compared to a previously determined reference range or control. ### Claim 3 (depends on 1) The method according to claim 1, wherein the step of detecting comprises: (a) contacting the sample with a capture reagent that is specific for a polypeptide as defined in claim 1; and (b) detecting whether binding has occurred between the capture reagent and said polypeptide in the sample. ### Claim 4 (depends on 3) The method according to claim 3, wherein step (b) comprises detecting the captured polypeptide using a directly or indirectly labelled detection reagent. ### Claim 5 (depends on 3) The method according to claim 3, wherein the capture reagent is immobilised on a solid phase. ### Claim 6 (depends on 1) The method according to claim 1, wherein the polypeptide is detected and/or quantified using an antibody that specifically binds to one or more CD27L polypeptides as defined in claim 1. ### Claim 7 (depends on 1) A method of screening for anti-epithelial-derived cancer agents that interact with a CD27L polypeptide as defined in claim 1, said method comprising: (a) contacting said polypeptide with a candidate agent; and (b) determining whether or not the candidate agent interacts with said polypeptide. ### Claim 8 (depends on 7) The method according to claim 7, wherein the determination of interaction between the candidate agent and CD27L polypeptide comprises quantitatively detecting binding of the candidate agent and said polypeptide. ### Claim 9 (depends on 1) A method of screening for anti-epithelial-derived cancer agents that modulate (a) the expression or activity of a CD27L polypeptide as defined in claim 1, comprising (i) comparing the expression or activity of said polypeptide in the presence of a candidate agent with the expression or activity of said polypeptide in the absence of the candidate agent or in the presence of a control agent; and (ii) determining whether the candidate agent causes the expression or activity of said polypeptide to change. ### Claim 10 (depends on 9) The method of claim 9, wherein the expression or activity level of said polypeptide is compared with a predetermined reference range. ### Claim 11 (depends on 9) The method of claim 9, which additionally comprises selecting an agent which modulates the expression or activity of said polypeptide for further testing, or therapeutic or prophylactic use as an anti-epithelial-derived cancer agent. ### Claim 12 (depends on 1) The method of claim 1, wherein the epithelial-derived cancer is selected from colorectal cancer and kidney cancer. ### Claim 13 (depends on 7) The method of claim 7, wherein the epithelial-derived cancer is selected from colorectal cancer and kidney cancer. ### Claim 14 (depends on 9) The method of claim 9, wherein the epithelial-derived cancer is selected from colorectal cancer and kidney cancer. ### Claim 15 (depends on 12) The method of claim 12, wherein the kidney cancer is renal cell carcinoma of the clear cell type. ### Claim 16 (depends on 13) The method of claim 13, wherein the kidney cancer is renal cell carcinoma of the clear cell type. ### Claim 17 (depends on 14) The method of claim 14, wherein the kidney cancer is renal cell carcinoma of the clear cell type.